Cardiopulmonary bypass and oxidative stress

Oxidative Medicine and Cellular Longevity

Volumn 2015, Issue , 2015, Pages

  Zakkar, Mustafa ^a   Guida, Gustavo ^a   Suleiman, M Saadeh ^a   Angelini, Gianni D ^a  

^a BRISTOL ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR SURGERY; CHEMICAL ACTIVATION; SURGERY;

ANTIOXIDANT PROPERTIES; CARDIAC SURGERY; CARDIOPLEGIA; CARDIOPULMONARY BYPASS; CLINICAL OUTCOME; PROINFLAMMATORY; PROINFLAMMATORY RESPONSE; SIGNALLING PATHWAYS;

OXIDATIVE STRESS;

REACTIVE OXYGEN METABOLITE; ANTIOXIDANT;

ARTICLE; CARDIOPLEGIA; CARDIOPULMONARY BYPASS; HEART MUSCLE; HEMOLYSIS; HUMAN; INFLAMMATION; INTERVENTION STUDY; INTRACELLULAR SIGNALING; KIDNEY; LEUKOCYTE ACTIVATION; LUNG; NONHUMAN; OUTCOME ASSESSMENT; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; SURVIVAL; ANIMAL; DRUG EFFECTS; ISCHEMIA; METABOLISM; PATHOLOGY;

ANIMALS; ANTIOXIDANTS; CARDIOPULMONARY BYPASS; HUMANS; INFLAMMATION; ISCHEMIA; NEUTROPHIL ACTIVATION; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

EID: 84923924459     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2015/189863     Document Type: Article

References (102)

1. L. H. Edmunds, "Cardiopulmonary bypass after 50 years," The New England Journal ofMedicine, vol. 351, no. 16, pp. 1603-1606, 2004.
2. R. C. Daly, J. A. Dearani, C. G. A. McGregor et al., "Fifty years of open heart surgery at theMayoClinic,"Mayo Clinic Proceedings, vol. 80, no. 5, pp. 636-640, 2005.
3. C. Baufreton, J.-J. Corbeau, and F. Pinaud, "Inflammatory response and haematological disorders in cardiac surgery: toward amore physiological cardiopulmonary bypass," Annales Francaises d'Anesthesie et de Reanimation, vol. 25, no. 5, pp. 510-520, 2006.
4. A. Dabbous, C. Kassas, and A. Baraka, "The inflammatory response after cardiac surgery," Middle East Journal of Anesthesiology, vol. 17, no. 2, pp. 233-254, 2003.
5. J. K. Kirklin and D. C. McGiffin, "Early complications following cardiac surgery," Cardiovascular Clinics, vol. 17, no. 3, pp. 321-343, 1987.
6. C. S. H. Ng and S. Wan, "Limiting inflammatory response to cardiopulmonary bypass: pharmaceutical strategies," Current Opinion in Pharmacology, vol. 12, no. 2, pp. 155-159, 2012.
7. M.-S. Suleiman, K. Zacharowski, and G. D. Angelini, "Inflammatory response and cardioprotection during open-heart surgery: the importance of anaesthetics," British Journal of Pharmacology, vol. 153, no. 1, pp. 21-33, 2008.
8. R. K. Gupta, A. K. Patel, N. Shah, A. K. Chaudhary, U. K. Jha, and U. C. Yadav, "Oxidative stress and antioxidants in disease and cancer: a review,"Asian Pacific Journal of Cancer Prevention, vol. 15, pp. 4405-4409, 2014.
9. M. Barzegar AmiriOlia, C. H. Schiesser, and M. K. Taylor, "New reagents for detecting free radicals and oxidative stress," Organic & Biomolecular Chemistry, vol. 45, no. 40, 2014.
10. G. Noctor, C. Lelarge-Trouverie, and A. Mhamdi, "The metabolomics of oxidative stress," Phytochemistry, 2014.
11. A. Nabeebaccus,M. Zhang, and A. M. Shah, "NADPH oxidases and cardiac remodelling," Heart Failure Reviews, vol. 16, no. 1, pp. 5-12, 2011.
12. Y. H. Zhang, C. Z. Jin, J. H. Jang, and Y. Wang, "Molecularmechanisms of neuronal nitric oxide synthase in cardiac function and pathophysiology," The Journal of Physiology, vol. 592, pp. 3189-3200, 2014.
13. T. A. Pearson, G. A. Mensah,R.W. Alexander et al., "Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the centers for disease control and prevention and the AmericanHeart Association," Circulation, vol. 107, no. 3, pp. 499-511, 2003.
14. D. Royston, "The inflammatory response and extracorporeal circulation," Journal of Cardiothoracic and Vascular Anesthesia, vol. 11, no. 3, pp. 341-354, 1997.
15. J. H. Levy and K. A. Tanaka, "Inflammatory response to cardiopulmonary bypass," The Annals of Thoracic Surgery, vol. 75, no. 2, pp. S715-S720, 2003.
16. Y. Haga, N. Hatori, H. Yoshizu, E. Okuda, Y. Uriuda, and S. Tanaka, "Granulocyte superoxide anion and elastase release during cardiopulmonary bypass," Artificial Organs, vol. 17, no. 10, pp. 837-842, 1993.
17. K. Kawahito, E. Kobayashi, M. Ohmori et al., "Enhanced responsiveness of circulatory neutrophils after cardiopulmonary bypass: increased aggregability and superoxide producing capacity," Artificial Organs, vol. 24, no. 1, pp. 37-42, 2000.
18. M.-S. Suleiman, A. P. Halestrap, and E. J. Griffiths, "Mitochondria: a target for myocardial protection," Pharmacology and Therapeutics, vol. 89, no. 1, pp. 29-46, 2001.
19. D. Gadaleta, A. L. Fahey, M. Verma et al., "Neutrophil leukotriene generation increases after cardiopulmonary bypass," The Journal of Thoracic and Cardiovascular Surgery, vol. 108, no. 4, pp. 642-647, 1994.
20. J.-M. Li, A. M. Mullen, S. Yun et al., "Essential role of the NADPH oxidase subunit p47phox in endothelial cell superoxide production in response to phorbol ester and tumor necrosis factor-α," Circulation Research, vol. 90, no. 2, pp. 143-150, 2002.
21. N. Marui, M. K. Offermann, R. Swerlick et al., "Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells," The Journal of Clinical Investigation, vol. 92, no. 4, pp. 1866-1874, 1993.
22. M. P. Soares,M. P. Seldon, I. P. Gregoire et al., "Heme oxygenase- 1 modulates the expression of adhesion molecules associated with endothelial cell activation," Journal of Immunology, vol. 172, no. 6, pp. 3553-3563, 2004.
23. H. Kamata, S.-I. Honda, S. Maeda, L. Chang, H. Hirata, and M. Karin, "Reactive oxygen species promote TNFα-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases," Cell, vol. 120, no. 5, pp. 649-661, 2005.
24. M. Saitoh,H. Nishitoh, M. Fujii et al., "Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1," The EMBO Journal, vol. 17, no. 9, pp. 2596-2606, 1998.
25. M. Grossmann, Y. Nakamura, R. Grumont, and S. Gerondakis, "New insights into the roles of ReL/NF-κB transcription factors in immune function, hemopoiesis and human disease," The International Journal of Biochemistry and Cell Biology, vol. 31, no. 10, pp. 1209-1219, 1999.
26. K. van der Heiden, S. Cuhlmann, L. A. Luong, M. Zakkar, and P. C. Evans, "Role of nuclear factor kappaB in cardiovascular health and disease," Clinical Science, vol. 118, no. 10, pp. 593-605, 2010.
27. P. J. Barnes and M. Karin, "Nuclear factor-κB-a pivotal transcription factor in chronic inflammatory diseases," TheNew England Journal ofMedicine, vol. 336, no. 15, pp. 1066-1071, 1997.
28. U. C. S. Yadav and K. V. Ramana, "Regulation of NF-κBinduced inflammatory signaling by lipid peroxidation-derived aldehydes," OxidativeMedicine and Cellular Longevity, vol. 2013, Article ID 690545, 11 pages, 2013.
29. N. Chaudhari, P. Talwar, A. Parimisetty, C. Lefebvre d'Hellencourt, and P. Ravanan, "A molecular web: endoplasmic reticulum stress, inflammation, and oxidative stress," Frontiers in Cellular Neuroscience, vol. 8, article 213, 2014.
30. M.-S. Suleiman, M. Hancock, R. Shukla, C. Rajakaruna, and G. D. Angelini, "Cardioplegic strategies to protect the hypertrophic heart during cardiac surgery," Perfusion, vol. 26, supplement 1, pp. 48-56, 2011.
31. M. Wang, L. Baker, B. M. Tsai, K. K. Meldrum, and D. R. Meldrum, "Sex differences in the myocardial inflammatory response to ischemia-reperfusion injury," The American Journal of Physiology-Endocrinology and Metabolism, vol. 288, no. 2, pp. E321-E326, 2005.
32. C. P. Connern and A. P. Halestrap, "Recruitment of mitochondrial cyclophilin to the mitochondrial inner membrane under conditions of oxidative stress that enhance the opening of a calcium-sensitive non-specific channel," The Biochemical Journal, vol. 302, part 2, pp. 321-324, 1994.
33. D. B. Zorov, C. R. Filburn, L.-O. Klotz, J. L. Zweier, and S. J. Sollott, "Reactive oxygen species (ROS)-induced ROS release: a new phenomenon accompanying induction of the mitochondrial permeability transition in cardiacmyocytes,"The Journal of Experimental Medicine, vol. 192, no. 7, pp. 1001-1014, 2000.
34. P. Pasdois, J. E. Parker, E. J. Griffiths, and A. P. Halestrap, "The role of oxidized cytochrome c in regulating mitochondrial reactive oxygen species production and its perturbation in ischaemia," The Biochemical Journal, vol. 436, no. 2, pp. 493-505, 2011.
35. A. P. Halestrap, S. J. Clarke, and S. A. Javadov, "Mitochondrial permeability transition pore opening during myocardial reperfusion-a target for cardioprotection," Cardiovascular Research, vol. 61, no. 3, pp. 372-385, 2004.
36. H. M. Honda, P. Korge, and J. N. Weiss, "Mitochondria and ischemia/reperfusion injury," Annals of the New York Academy of Sciences, vol. 1047, pp. 248-258, 2005.
37. J. F. Hoffman, "Cation transport and structure of the red-cell plasma membrane," Circulation, vol. 26, pp. 1202-1213, 1962.
38. R. I. Weed, "Membrane structure and its relation to haemolysis," Clinics in Haematology, vol. 4, pp. 3-28, 1975.
39. A. M. Morariu, Y. J. Gu, R. C. G. G. Huet, W. A. Siemons, G. Rakhorst, and W. V. Oeveren, "Red blood cell aggregation during cardiopulmonary bypass: a pathogenic cofactor in endothelial cell activation?" European Journal of Cardio- Thoracic Surgery, vol. 26, no. 5, pp. 939-946, 2004.
40. S. Saraf, D. Wellsted, S. Sharma, and D. A. Gorog, "Shearinduced global thrombosis test of native blood: pivotal role of ADP allows monitoring of P2Y12 antagonist therapy," Thrombosis Research, vol. 124, no. 4, pp. 447-451, 2009.
41. O. K. Baskurt and H. J. Meiselman, "Blood rheology and hemodynamics," Seminars in Thrombosis and Hemostasis, vol. 29, no. 5, pp. 435-450, 2003.
42. H. Relevy, A. Koshkaryev, N. Manny, S. Yedgar, and G. Barshtein, "Blood banking-induced alteration of red blood cell flow properties," Transfusion, vol. 48, no. 1, pp. 136-146, 2008.
43. K. Karkouti, "Transfusion and risk of acute kidney injury in cardiac surgery," British Journal of Anaesthesia, vol. 109, no. 1, supplement, pp. i29-i38, 2012.
44. Y. M. Kim, H. Kattach, C. Ratnatunga, R. Pillai, K.M. Channon, and B. Casadei, "Association of atrial nicotinamide adenine dinucleotide phosphate oxidase activity with the development of atrial fibrillation after cardiac surgery," Journal of the American College of Cardiology, vol. 51, no. 1, pp. 68-74, 2008.
45. D. Montaigne, X. Marechal, P. Lefebvre et al., "Mitochondrial dysfunction as an arrhythmogenic substrate: a translational proof-of-concept study in patients with metabolic syndrome in whom post-operative atrial fibrillation develops," Journal of the American College of Cardiology, vol. 62, no. 16, pp. 1466-1473, 2013.
46. R. Nowicki, J. Saczko, J. Kulbacka et al., "The estimation of oxidative stress markers and apoptosis in right atrium auricles cardiomyocytes of patients undergoing surgical heart revascularisation with the use of warm blood cardioplegia," Folia Histochemica et Cytobiologica, vol. 48, no. 2, pp. 202-207, 2010.
47. M. E. Callister, A. Burke-Gaffney, G. J. Quinlan et al., "Extracellular thioredoxin levels are increased in patients with acute lung injury," Thorax, vol. 61, no. 6, pp. 521-527, 2006.
48. N. J. Lamb, J. M. C. Gutteridge, C. Baker, T.W. Evans, and G. J. Quinlan, "Oxidative damage to proteins of bronchoalveolar lavage fluid in patients with acute respiratory distress syndrome: evidence for neutrophil-mediated hydroxylation, nitration, and chlorination," Critical Care Medicine, vol. 27, no. 9, pp. 1738-1744, 1999.
49. G. J. Quinlan, N. J. Lamb, T.W. Evans, and J. M. C. Gutteridge, "Plasma fatty acid changes and increased lipid peroxidation in patients with adult respiratory distress syndrome," Critical Care Medicine, vol. 24, no. 2, pp. 241-246, 1996.
50. M. T. Ghorbel, N. N. Patel, M. Sheikh, G. D. Angelini, M. Caputo, and G. J. Murphy, "Changes in renal medulla gene expression in a pre-clinical model of post cardiopulmonary bypass acute kidney injury,"BMC Genomics, vol. 15,no. 1, article 916, 2014.
51. S. Romagnoli and Z. Ricci, "Postoperative acute kidney injury," Minerva Anestesiologica, 2014.
52. J. V. Bonventre and A. Zuk, "Ischemic acute renal failure: an inflammatory disease?" Kidney International, vol. 66, no. 2, pp. 480-485, 2004.
53. E. Ozbek, "Induction of oxidative stress in kidney," International Journal ofNephrology, vol. 2012,Article ID465897, 9 pages, 2012.
54. H. Mao, N. Katz, W. Ariyanon et al., "Cardiac surgeryassociated acute kidney injury," CardioRenal Medicine, vol. 3, no. 3, pp. 178-199, 2013.
55. P. Devarajan, "Update onmechanisms of ischemic acute kidney injury," Journal of theAmericanSociety of Nephrology, vol. 17,no. 6, pp. 1503-1520, 2006.
56. Y.-C. Li, P. Ridefelt, L. Wiklund, and G. Bjerneroth, "Propofol induces a lowering of free cytosolic calciuminmyocardial cells," Acta Anaesthesiologica Scandinavica, vol. 41, no. 5, pp. 633-638, 1997.
57. N. Kokita and A. Hara, "Propofol attenuates hydrogen peroxideinduced mechanical and metabolic derangements in the isolated rat heart," Anesthesiology, vol. 84, no. 1, pp. 117-127, 1996.
58. N. Kokita, A. Hara, Y. Abiko, J. Arakawa, H. Hashizume, and A. Namiki, "Propofol improves functional and metabolic recovery in ischemic reperfused isolated rat hearts," Anesthesia and Analgesia, vol. 86, no. 2, pp. 252-258, 1998.
59. P. G. Murphy, D. S. Myers, M. J. Davies, N. R. Webster, and J. G. Jones, "The antioxidant potential of propofol (2,6- diisopropylphenol)," British Journal of Anaesthesia, vol. 68, no. 6, pp. 613-618, 1992.
60. O. Eriksson, P. Pollesello, and N.-E. L. Saris, "Inhibition of lipid peroxidation in isolated rat liver mitochondria by the general anaesthetic propofol," Biochemical Pharmacology, vol. 44, no. 2, pp. 391-393, 1992.
61. T. R. Green, I. S. R. Bennett, and V. M. Nelson, "Specificity and properties of propofol as an antioxidant free radical scavenger," Toxicology and Applied Pharmacology, vol. 129, no. 1, pp. 163-169, 1994.
62. S. Zhao, L.-J. Xie, J.-X. Zhang, and L.-F. Li, "Effects of propofol on the activation of nuclear factor-kappaB and cardiomyocytes apoptosis during myocardial ischemia/reperfusion injury in rats," Zhongguo Ying Yong Sheng Li Xue Za Zhi, vol. 26, no. 3, pp. 291-295, 2010.
63. T. D. Runzer, D. M. Ansley, D. V. Godin, and G. K. Chambers, "Tissue antioxidant capacity during anesthesia: propofol enhances in vivo red cell and tissue antioxidant capacity in a rat model," Anesthesia & Analgesia, vol. 94, no. 1, pp. 89-93, 2002.
64. Z. Xia, Z. Huang, and D. M. Ansley, "Large-dose propofol during cardiopulmonary bypass decreases biochemical markers ofmyocardial injury in coronary surgery patients: a comparison with isoflurane," Anesthesia and Analgesia, vol. 103, no. 3, pp. 527-532, 2006.
65. S. A. Javadov, K. H. H. Lim, P. M. Kerr, M.-S. Suleiman, G. D. Angelini, and A. P. Halestrap, "Protection of hearts from reperfusion injury by propofol is associated with inhibition of the mitochondrial permeability transition," Cardiovascular Research, vol. 45, no. 2, pp. 360-369, 2000.
66. K. H. H. Lim, A. P. Halestrap, G. D. Angelini, and M.-S. Suleiman, "Propofol is cardioprotective in a clinically relevant model of normothermic blood cardioplegic arrest and cardiopulmonary bypass," Experimental Biology andMedicine, vol. 230, no. 6, pp. 413-420, 2005.
67. Z. E. Plummer, S. Baos, C. A. Rogers et al., "The effects of propofol cardioplegia on blood and myocardial biomarkers of stress and injury in patientswith isolated coronary artery bypass grafting or aortic valve replacement using cardiopulmonary bypass: protocol for a single-center randomized controlled trial," JMIR Research Protocols, vol. 3, no. 3, article e35, 2014.
68. V. Cavalca, E. Tremoli, B. Porro et al., "Oxidative stress and nitric oxide pathway in adult patients who are candidates for cardiac surgery: patterns and differences," Interactive Cardio- Vascular andThoracic Surgery, vol. 17, no. 6, pp. 923-930, 2013.
69. I. Karu, G. Taal, K. Zilmer, C. Pruunsild, J. Starkopf, and M. Zilmer, "Inflammatory/oxidative stress during the first week after different types of cardiac surgery," Scandinavian Cardiovascular Journal, vol. 44, no. 2, pp. 119-124, 2010.
70. D. S. Lim, S. J. Mooradian, C. S. Goldberg et al., "Effect of oral L-arginine on oxidant stress, endothelial dysfunction, and systemic arterial pressure in young cardiac transplant recipients," The American Journal of Cardiology, vol. 94, no. 6, pp. 828-831, 2004.
71. S. Doutreleau,O. Rouyer, P. DiMarco et al., "L-Arginine supplementation improves exercise capacity after a heart transplant," The American Journal of Clinical Nutrition, vol. 91, no. 5, pp. 1261-1267, 2010.
72. U. Kiziltepe, B. Tunçtan, Z. B. Eyileten et al., "Efficiency of Larginine enriched cardioplegia and non-cardioplegic reperfusion in ischemic hearts," International Journal of Cardiology, vol. 97, no. 1, pp. 93-100, 2004.
73. M. Carrier, L. P. Perrault, A. Fortier, D. Bouchard, and M. Pellerin, "L-arginine supplemented nondiluted blood cardioplegia: a clinical trial," Journal of Cardiovascular Surgery, vol. 51, no. 2, pp. 283-287, 2010.
74. D. T. Andrews, J. Sutherland, P. Dawson, A. G. Royse, and C. F. Royse, "L-arginine cardioplegia reduces oxidative stress and preserves diastolic function in patients with low ejection fraction undergoing coronary artery surgery," Anaesthesia and Intensive Care, vol. 40, no. 1, pp. 99-106, 2012.
75. G. Orhan,N. Yapici,M. Yuksel et al., "EffectsofN-acetylcysteine on myocardial ischemia-reperfusion injury in bypass surgery," Heart and Vessels, vol. 21, no. 1, pp. 42-47, 2006.
76. O. Peker, T. Peker, D. Erdogan et al., "Effects of intravenous N-acetylcysteine on periprocedural myocardial injury after on-pump coronary artery by-pass grafting," The Journal of Cardiovascular Surgery, vol. 49, no. 4, pp. 527-531, 2008.
77. A. Prabhu, D. I. Sujatha, N. Kanagarajan, M. A. Vijayalakshmi, and B. Ninan, "Effect of N-acetylcysteine in attenuating ischemic reperfusion injury in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass," Annals of Vascular Surgery, vol. 23, no. 5, pp. 645-651, 2009.
78. A. J. Rodrigues, P. R. B. Évora, S. Bassetto et al., "Blood cardioplegia with N-acetylcysteine may reduce coronary endothelial activation and myocardial oxidative stress," The Heart Surgery Forum, vol. 12, no. 1, pp. E44-E48, 2009.
79. A. Vento, A. Nemlander, J. Aittomäki, J. Salo, J. Karhunen, and O. J. Rämö, "N-acetylcysteine as an additive to crystalloid cardioplegia increased oxidative stress capacity in CABG patients," Scandinavian Cardiovascular Journal, vol. 37,no. 6, pp. 349-355, 2003.
80. E. Grossini, C. Molinari, P. P. Caimmi, F. Uberti, and G. Vacca, "Levosimendan induces NO production through p38 MAPK, ERK and Akt in porcine coronary endothelial cells: role for mitochondrial KATP channel," British Journal of Pharmacology, vol. 156, no. 2, pp. 250-261, 2009.
81. A. Hönisch, N. Theuring, B. Ebner, C. Wagner, R. H. Strasser, and C. Weinbrenner, "Postconditioning with levosimendan reduces the infarct size involving the PI3K pathway and KATPchannel activation but is independent of PDE-III inhibition," Basic Research in Cardiology, vol. 105, no. 2, pp. 155-167, 2010.
82. J. D. McCully and S. Levitsky, "The mitochondrial KATP channel and cardioprotection," The Annals of Thoracic Surgery, vol. 75, no. 2, pp. S667-S673, 2003.
83. K. D. Garlid and P. Paucek, "Mitochondrial potassium transport: The K+ cycle," Biochimica et Biophysica Acta, vol. 1606, no. 1-3, pp. 23-41, 2003.
84. A. P. Halestrap, "The regulation of the oxidation of fatty acids and other substrates in rat heart mitochondria by changes in the matrix volume induced by osmotic strength, valinomycin and Ca2+," The Biochemical Journal, vol. 244, no. 1, pp. 159-164, 1987.
85. T. Miura, Y. Liu, M. Goto et al., "Mitochondrial ATP-sensitive K+ channels play a role in cardioprotection byNa+-H+ exchange inhibition against ischemia/reperfusion injury," Journal of the American College of Cardiology, vol. 37, no. 3, pp. 957-963, 2001.
86. S.-X. Shao, L. Zhang, H.-X. Chen et al., "Diazoxide pretreatment enhances L6 skeletal myoblast survival and inhibits apoptosis induced by hydrogen peroxide," Anatomical Record, vol. 295, no. 4, pp. 632-640, 2012.
87. H. I. Eriksson, J. R. Jalonen, L. O. Heikkinen et al., "Levosimendan facilitates weaning from cardiopulmonary bypass in patients undergoing coronary artery bypass grafting with impaired left ventricular function," Annals of Thoracic Surgery, vol. 87, no. 2, pp. 448-454, 2009.
88. L. Tritapepe, V. de Santis, D. Vitale et al., "Levosimendan pretreatment improves outcomes in patients undergoing coronary artery bypass graft surgery," British Journal of Anaesthesia, vol. 102, no. 2, pp. 198-204, 2009.
89. A. Akgul, L. Mavioglu, S. F. Katircioglu, M. Pac, and A. Cobanoglu, "Levosimendan for weaning from cardiopulmonary bypass after coronary artery bypass grafting," Heart Lung and Circulation, vol. 15, no. 5, pp. 320-324, 2006.
90. S.G. DeHert, S. Lorsomradee, H. vandenEede, S. Cromheecke, and P. J. Van der Linden, "A randomized trial evaluating different modalities of levosimendan administration in cardiac surgery patients with myocardial dysfunction," Journal of Cardiothoracic and Vascular Anesthesia, vol. 22, pp. 699-705, 2008.
91. Z.-Z. Niu, S.-M. Wu, W.-Y. Sun, W.-M. Hou, and Y.-F. Chi, "Perioperative levosimendan therapy is associated with a lower incidence of acute kidney injury after cardiac surgery: a metaanalysis," Journal of Cardiovascular Pharmacology, vol. 63,no. 2, pp. 107-112, 2014.
92. M. P. Murphy and R. A. J. Smith, "Targeting antioxidants to mitochondria by conjugation to lipophilic cations," Annual Review of Pharmacology and Toxicology, vol. 47, pp. 629-656, 2007.
93. R. A. J. Smith, R. C. Hartley, and M. P. Murphy, "Mitochondriatargeted small molecule therapeutics and probes," Antioxidants and Redox Signaling, vol. 15, no. 12, pp. 3021-3038, 2011.
94. R. A. J. Smith and M. P. Murphy, "Animal and human studies with the mitochondria-targeted antioxidant MitoQ," Annals of the New York Academy of Sciences, vol. 1201, pp. 96-103, 2010.
95. D. Graham, N. N. Huynh, C. A. Hamilton et al., "Mitochondriatargeted antioxidant mitoq10 improves endothelial function and attenuates cardiac hypertrophy," Hypertension, vol. 54, no. 2, pp. 322-328, 2009.
96. V. J. Adlam, J. C. Harrison, C. M. Porteous et al., "Targeting an antioxidant to mitochondria decreases cardiac ischemiareperfusion injury," The FASEB Journal, vol. 19, no. 9, pp. 1088-1095, 2005.
97. G. S. Supinski, M. P. Murphy, and L. A. Callahan, "MitoQ administration prevents endotoxin-induced cardiac dysfunction," American Journal of Physiology-Regulatory Integrative and Comparative Physiology, vol. 297, no. 4, pp. R1095-R1102, 2009.
98. E. J. Gane, F. Weilert, D. W. Orr et al., "The mitochondriatargeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients," Liver International, vol. 30, no. 7, pp. 1019-1026, 2010.
99. H. A. Vohra, R. Whistance, A. Modi, and S. K. Ohri, "The inflammatory response to miniaturised extracorporeal circulation: a review of the literature," Mediators of Inflammation, vol. 2009, Article ID 707042, 7 pages, 2009.
100. B. Kiaii, S. Fox, S. A. Swinamer et al., "The early inflammatory response in a mini-cardiopulmonary bypass system: a prospective randomized study," Innovations, vol. 7, no. 1,pp. 23-32, 2012.
101. W. B. Gerritsen, W.-J. P. van Boven, D. S. Boss, F. J. Haas, E. P. van Dongen, and L. P. Aarts, "Malondialdehyde in plasma, a biomarker of global oxidative stress during mini-CABG compared to on- and off-pump CABG surgery: a pilot study," Interactive Cardiovascular andThoracic Surgery, vol. 5, no. 1, pp. 27-31, 2006.
102. W.-J. van Boven, W. B. Gerritsen, F. G. Waanders, F. J. Haas, and L. P. Aarts, "Mini extracorporeal circuit for coronary artery bypass grafting: initial clinical and biochemical results: a comparison with conventional and off-pump coronary artery bypass grafts concerning global oxidative stress and alveolar function," Perfusion, vol. 19, no. 4, pp. 239-246, 2004.